Insmed Incorporated (0JAV.L)
USD 71.8
(-4.53%)
USD 71.8
(-4.53%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 305.2 Million USD | 24.39% |
| 2022 | 245.35 Million USD | 30.19% |
| 2021 | 188.46 Million USD | 14.63% |
| 2020 | 164.41 Million USD | 20.48% |
| 2019 | 136.46 Million USD | 1287.56% |
| 2018 | 9.83 Million USD | 0.0% |
| 2017 | - USD | 0.0% |
| 2016 | - USD | 0.0% |
| 2015 | - USD | -100.0% |
| 2014 | 11.5 Million USD | 0.0% |
| 2013 | 11.5 Million USD | 0.0% |
| 2012 | - USD | -100.0% |
| 2011 | 4.41 Million USD | -36.18% |
| 2010 | 6.92 Million USD | -33.28% |
| 2009 | 10.37 Million USD | -11.33% |
| 2008 | 11.69 Million USD | 55.39% |
| 2007 | 7.52 Million USD | 659.74% |
| 2006 | 991 Thousand USD | 656.49% |
| 2005 | 131 Thousand USD | -4.38% |
| 2004 | 137 Thousand USD | -8.67% |
| 2003 | 150 Thousand USD | -92.33% |
| 2002 | 1.95 Million USD | 560.47% |
| 2001 | 296 Thousand USD | 393.33% |
| 2000 | 60 Thousand USD | -90.95% |
| 1999 | 663.16 Thousand USD | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 90.34 Million USD | 19.66% |
| 2024 Q1 | 75.5 Million USD | -9.79% |
| 2024 Q3 | 93.42 Million USD | 3.41% |
| 2023 Q2 | 77.22 Million USD | 18.42% |
| 2023 Q4 | 83.69 Million USD | 5.84% |
| 2023 Q3 | 79.07 Million USD | 2.39% |
| 2023 FY | 305.2 Million USD | 24.39% |
| 2023 Q1 | 65.21 Million USD | 9.97% |
| 2022 Q1 | 53.1 Million USD | -5.38% |
| 2022 FY | 245.35 Million USD | 30.19% |
| 2022 Q4 | 59.3 Million USD | -12.45% |
| 2022 Q3 | 67.73 Million USD | 3.85% |
| 2022 Q2 | 65.22 Million USD | 22.81% |
| 2021 FY | 188.46 Million USD | 14.63% |
| 2021 Q3 | 46.75 Million USD | 3.07% |
| 2021 Q4 | 56.12 Million USD | 20.03% |
| 2021 Q2 | 45.36 Million USD | 12.81% |
| 2021 Q1 | 40.21 Million USD | -2.9% |
| 2020 Q3 | 43.64 Million USD | 2.7% |
| 2020 Q1 | 36.86 Million USD | -19.36% |
| 2020 Q4 | 41.41 Million USD | -5.11% |
| 2020 Q2 | 42.49 Million USD | 15.29% |
| 2020 FY | 164.41 Million USD | 20.48% |
| 2019 Q2 | 29.97 Million USD | 36.85% |
| 2019 Q4 | 45.7 Million USD | 17.55% |
| 2019 FY | 136.46 Million USD | 1287.56% |
| 2019 Q3 | 38.88 Million USD | 29.74% |
| 2019 Q1 | 21.9 Million USD | 122.69% |
| 2018 Q2 | - USD | 0.0% |
| 2018 Q1 | - USD | 0.0% |
| 2018 FY | 9.83 Million USD | 0.0% |
| 2018 Q4 | 9.83 Million USD | 0.0% |
| 2018 Q3 | - USD | 0.0% |
| 2017 FY | - USD | 0.0% |
| 2017 Q1 | - USD | 0.0% |
| 2017 Q4 | - USD | 0.0% |
| 2017 Q2 | - USD | 0.0% |
| 2017 Q3 | - USD | 0.0% |
| 2016 Q4 | - USD | 0.0% |
| 2016 Q3 | - USD | 0.0% |
| 2016 FY | - USD | 0.0% |
| 2016 Q1 | - USD | 0.0% |
| 2016 Q2 | - USD | 0.0% |
| 2015 Q3 | - USD | 0.0% |
| 2015 Q1 | - USD | -100.0% |
| 2015 Q4 | - USD | 0.0% |
| 2015 FY | - USD | -100.0% |
| 2015 Q2 | - USD | 0.0% |
| 2014 Q2 | - USD | 0.0% |
| 2014 Q4 | 11.5 Million USD | 0.0% |
| 2014 FY | 11.5 Million USD | 0.0% |
| 2014 Q1 | - USD | 100.0% |
| 2014 Q3 | - USD | 0.0% |
| 2013 Q1 | - USD | 0.0% |
| 2013 FY | 11.5 Million USD | 0.0% |
| 2013 Q4 | -11.49 Million USD | 0.0% |
| 2013 Q3 | - USD | -100.0% |
| 2013 Q2 | 11.5 Million USD | 0.0% |
| 2012 Q2 | - USD | 0.0% |
| 2012 Q1 | - USD | -100.0% |
| 2012 FY | - USD | -100.0% |
| 2012 Q4 | - USD | 0.0% |
| 2012 Q3 | - USD | 0.0% |
| 2011 FY | 4.41 Million USD | -36.18% |
| 2011 Q2 | 978 Thousand USD | -38.91% |
| 2011 Q1 | 1.6 Million USD | 21.2% |
| 2011 Q3 | 435 Thousand USD | -55.52% |
| 2011 Q4 | 1.4 Million USD | 222.53% |
| 2010 Q1 | 1.92 Million USD | -22.47% |
| 2010 Q4 | 1.32 Million USD | -26.9% |
| 2010 FY | 6.92 Million USD | -33.28% |
| 2010 Q2 | 1.86 Million USD | -3.37% |
| 2010 Q3 | 1.8 Million USD | -3.06% |
| 2009 Q4 | 2.48 Million USD | 0.53% |
| 2009 FY | 10.37 Million USD | -11.33% |
| 2009 Q2 | 3.04 Million USD | 28.27% |
| 2009 Q1 | 2.37 Million USD | -17.1% |
| 2009 Q3 | 2.47 Million USD | -18.59% |
| 2008 Q4 | 2.85 Million USD | -29.77% |
| 2008 Q2 | 2.64 Million USD | 14.29% |
| 2008 Q3 | 4.07 Million USD | 53.74% |
| 2008 Q1 | 2.31 Million USD | 8.17% |
| 2008 FY | 11.69 Million USD | 55.39% |
| 2007 Q4 | 2.14 Million USD | 47.52% |
| 2007 Q3 | 1.45 Million USD | -36.18% |
| 2007 Q2 | 2.27 Million USD | 37.05% |
| 2007 Q1 | 1.66 Million USD | 230.68% |
| 2007 FY | 7.52 Million USD | 659.74% |
| 2006 Q3 | 226 Thousand USD | 7.62% |
| 2006 Q2 | 210 Thousand USD | 288.89% |
| 2006 Q1 | 54 Thousand USD | 125.0% |
| 2006 Q4 | 502 Thousand USD | 122.12% |
| 2006 FY | 991 Thousand USD | 656.49% |
| 2005 Q1 | 57 Thousand USD | 147.83% |
| 2005 Q2 | 28 Thousand USD | -50.88% |
| 2005 FY | 131 Thousand USD | -4.38% |
| 2005 Q3 | 22 Thousand USD | -21.43% |
| 2005 Q4 | 24 Thousand USD | 9.09% |
| 2004 Q2 | 29 Thousand USD | -52.46% |
| 2004 Q1 | 61 Thousand USD | 125.93% |
| 2004 FY | 137 Thousand USD | -8.67% |
| 2004 Q3 | 24 Thousand USD | -17.24% |
| 2004 Q4 | 23 Thousand USD | -4.17% |
| 2003 Q1 | 62 Thousand USD | 138.46% |
| 2003 FY | 150 Thousand USD | -92.33% |
| 2003 Q4 | 27 Thousand USD | 0.0% |
| 2003 Q3 | 27 Thousand USD | -20.59% |
| 2003 Q2 | 34 Thousand USD | -45.16% |
| 2002 Q1 | 102 Thousand USD | 67.21% |
| 2002 Q2 | 70 Thousand USD | -31.37% |
| 2002 FY | 1.95 Million USD | 560.47% |
| 2002 Q4 | 26 Thousand USD | -98.52% |
| 2002 Q3 | 1.75 Million USD | 2410.0% |
| 2001 FY | 296 Thousand USD | 393.33% |
| 2001 Q4 | 61 Thousand USD | -7.58% |
| 2001 Q3 | 66 Thousand USD | -4.35% |
| 2001 Q2 | 69 Thousand USD | -31.0% |
| 2001 Q1 | 100 Thousand USD | 220.48% |
| 2000 FY | 60 Thousand USD | -90.95% |
| 2000 Q4 | -83 Thousand USD | -256.6% |
| 2000 Q3 | 53 Thousand USD | 5200.0% |
| 2000 Q1 | 90 Thousand USD | 0.0% |
| 2000 Q2 | 1000.00 USD | -98.89% |
| 1999 Q1 | 168 Thousand USD | 0.0% |
| 1999 FY | 663.16 Thousand USD | 0.0% |
| 1999 Q2 | 236 Thousand USD | 40.48% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Editas Medicine, Inc. | 78.12 Million USD | -290.676% |
| Dynavax Technologies Corporation | 232.28 Million USD | -31.394% |
| Supernus Pharmaceuticals, Inc. | 607.52 Million USD | 49.762% |
| Perrigo Company plc | 4.65 Billion USD | 93.444% |
| Illumina, Inc. | 4.5 Billion USD | 93.224% |
| Thermo Fisher Scientific Inc. | 42.85 Billion USD | 99.288% |
| Iovance Biotherapeutics, Inc. | 1.18 Million USD | -25569.302% |
| Walgreens Boots Alliance, Inc. | 147.65 Billion USD | 99.793% |
| IQVIA Holdings Inc. | 14.98 Billion USD | 97.963% |
| Heron Therapeutics, Inc. | 127.04 Million USD | -140.238% |
| Regeneron Pharmaceuticals, Inc. | 13.11 Billion USD | 97.673% |
| Unity Biotechnology, Inc. | - USD | -Infinity% |
| Waters Corporation | 2.95 Billion USD | 89.676% |
| Biogen Inc. | 9.83 Billion USD | 96.897% |
| Sangamo Therapeutics, Inc. | 176.23 Million USD | -73.185% |
| Evolus, Inc. | 202.08 Million USD | -51.03% |
| Adicet Bio, Inc. | - USD | -Infinity% |
| Cara Therapeutics, Inc. | 20.96 Million USD | -1355.589% |
| bluebird bio, Inc. | 29.49 Million USD | -934.709% |
| Esperion Therapeutics, Inc. | 116.33 Million USD | -162.355% |
| FibroGen, Inc. | 147.75 Million USD | -106.568% |
| Agilent Technologies, Inc. | 6.83 Billion USD | 95.533% |
| Corbus Pharmaceuticals Holdings, Inc. | - USD | -Infinity% |
| Homology Medicines, Inc. | -6.65 Million USD | 4688.904% |
| Geron Corporation | 237 Thousand USD | -128679.747% |
| Alnylam Pharmaceuticals, Inc. | 1.82 Billion USD | 83.306% |
| Amicus Therapeutics, Inc. | 399.35 Million USD | 23.575% |
| Myriad Genetics, Inc. | 678.4 Million USD | 55.011% |
| Viking Therapeutics, Inc. | - USD | -Infinity% |
| Intellia Therapeutics, Inc. | 36.27 Million USD | -741.373% |
| Zoetis Inc. | 8.54 Billion USD | 96.428% |
| Abeona Therapeutics Inc. | 3.5 Million USD | -8620.229% |
| Mettler-Toledo International Inc. | 3.78 Billion USD | 91.943% |
| BioMarin Pharmaceutical Inc. | 2.41 Billion USD | 87.384% |
| Vertex Pharmaceuticals Incorporated | 9.86 Billion USD | 96.907% |
| Kala Pharmaceuticals, Inc. | - USD | -Infinity% |
| Ionis Pharmaceuticals, Inc. | 787.64 Million USD | 61.251% |
| Atara Biotherapeutics, Inc. | 8.57 Million USD | -3460.107% |
| Verastem, Inc. | - USD | -Infinity% |
| Nektar Therapeutics | 90.12 Million USD | -238.661% |
| Axsome Therapeutics, Inc. | 270.6 Million USD | -12.789% |
| Aclaris Therapeutics, Inc. | 31.24 Million USD | -876.697% |
| Sarepta Therapeutics, Inc. | 1.24 Billion USD | 75.452% |
| OPKO Health, Inc. | 863.49 Million USD | 64.654% |
| Exelixis, Inc. | 1.83 Billion USD | 83.324% |
| Neurocrine Biosciences, Inc. | 1.88 Billion USD | 83.827% |
| Corcept Therapeutics Incorporated | 482.37 Million USD | 36.728% |
| Anavex Life Sciences Corp. | - USD | -Infinity% |
| uniQure N.V. | 15.84 Million USD | -1826.453% |
| Imunon, Inc. | - USD | -Infinity% |
| Blueprint Medicines Corporation | 249.38 Million USD | -22.387% |
| Halozyme Therapeutics, Inc. | 829.25 Million USD | 63.195% |
| Agios Pharmaceuticals, Inc. | 26.82 Million USD | -1037.859% |
| TG Therapeutics, Inc. | 233.66 Million USD | -30.619% |
| Incyte Corporation | 3.69 Billion USD | 91.741% |
| Emergent BioSolutions Inc. | 1.04 Billion USD | 70.913% |